Trial Profile
Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2017
Price :
$35
*
At a glance
- Drugs Galicaftor (Primary) ; GLPG 2451 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Galapagos NV
- 12 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Jul 2017 New trial record